|
|
|
|
|
|
Tech took a beating this week. The Nasdaq Composite fell 2.6% on Thursday, its steepest drop since June, and the VIX jumped about 14%.
But scroll past the wreckage, and you'll find a mid-cap services name near the top of my watchlist. It trades at roughly two-thirds of the average analyst price target, pays a dividend yielding about 2%, and reports fiscal Q4 next month. CNBC isn't talking about it. Good.
|
| |
|
| |
|
|
|
Meet a Company That Runs the Plumbing of American Government
Maximus, Inc. (NYSE: MMS) is the vendor behind the curtain for a huge chunk of American government services. Ever applied for Medicaid? Enrolled in a federal student loan program? Called a state workforce office? Decent odds Maximus was the operator on your end of the line.
They run back-office tech and call-center operations for government health, employment, and benefits programs across the U.S., U.K., and Australia. Not sexy. Not AI. But very sticky, and that stickiness is what you're buying.
The market's treating it like a value trap. Fundamentals say it's anything but.
Why This Name Keeps Getting Overlooked
Maximus has three strikes against it right now. It's not AI. It's not consumer. And in August, management cut its fiscal 2026 profit outlook after the Department of Veterans Affairs paused performance incentives on its big Medical Disability Exam contract starting July 1.
That combination has the stock around $63, down about 27% this year and well below its 52-week high near $99, even after a roughly 18% bounce over the past month.
Here's what matters structurally for you. Maximus contracts are typically multi-year, and the policy calendar is moving its way. Federal Medicaid work requirements start phasing in for states in 2027, which means more eligibility checks and more paperwork. That is exactly the work Maximus processes at scale, so treat it as a revenue runway, not a cliff.
Management has been buying back stock and leaning into clinical services, the higher-margin piece. That mix shift is the part of the story the market keeps skipping past.
The average analyst price target sits around $92, roughly 46% above the current price. You don't need that whole gap to close for this to work, as long as the cash flows hold.
Beyond GLP-1 (Sponsored)
Peptides are the body's own signaling molecules, re-engineered into precise, scalable medicines.
They are the technology behind today's GLP-1 treatments and a growing pipeline of therapies well beyond obesity.
Explore PEPT
The Numbers That Make the Case
Maximus trades at under 8x forward earnings. That's a melting-ice-cube multiple, not what you'd expect from a company still throwing off steady free cash flow. Market cap sits around $3.3 billion. Firmly in the ignored middle.
Too small for mega-cap index flows, too mundane for the small-cap momentum crowd.
Management has been using cash for buybacks on top of the dividend. Strip out the VA contract noise, and you've got a steady operator with recurring revenue and real pricing power at contract renewal.
Action: Build between $60 and $64 ahead of fiscal Q4 earnings on November 19. Use any further weakness to add. |
|
| |
|
| |
|
|
|
The Catalyst Coming in Weeks
Maximus runs a September fiscal year, so Q4 drops November 19, 2026. That's the catalyst.
Three things to watch in the reaction. First, any update on the VA Medical Disability Exam rebid and when the paused incentives come back. Second, operating margin in U.S. Services, where the clinical mix shows up. Third, the first read on fiscal 2027 guidance.
Setups like this get ignored for a reason. Expectations are on the floor. Sell-side coverage is thin. A clean beat with an upbeat guide can move the stock quickly because there aren't many sellers left after a year of underperformance.
Would you rather a company suspend its dividend for a year to fund growth, or keep paying it but take on more debt to do so?
Grid Pressure (Sponsored)
One chatbot question, and a server warehouse somewhere in America draws on the grid. Scale that across hundreds of millions of people daily.
Name the stock by text.
Data centers used 4.4% of U.S. electricity in 2023, per Lawrence Berkeley National Laboratory. Its 2028 projection: up to 12%.
Send the ticker and story.
Close to a tripling in five years, on a grid that was not built for it. One company sits right where that power comes from.
Which energy company is it?
*This ad is sent on behalf of Guardian Financial Publishing LLC, doing business as Stable Financial Publishing, 1013 Centre Road Suite 403-D, Wilmington, DE 19805. Nothing here is investment, financial, legal, or tax advice, and it is not a recommendation or solicitation to buy or sell any security. Investing involves substantial risk, including loss of principal; past performance does not guarantee future results. Data-center electricity figures are third-party estimates and projections, and AI IPO timing reflects investor expectations, not company guidance. References to OpenAI, Anthropic and Lawrence Berkeley National Laboratory are for informational purposes only; Stable Financial Publishing is not affiliated with, endorsed by, or sponsored by OpenAI, Anthropic or Lawrence Berkeley National Laboratory. Stable Financial Publishing, its owners, employees and contributors may hold positions in securities mentioned and may trade them at any time. Privacy: https://guardian.pub/privacy-policy/ · Terms: https://guardian.pub/terms-of-service/
Where the Operating Leverage Shows Up
The interesting part of Maximus isn't top-line growth. It's margin expansion.
The clinical services business, which runs independent medical reviews and assessments, carries materially higher margins than old-school contact-center work. As that segment grows faster than the overall mix, you get built-in margin uplift without signing a single new contract.
Throw in the buyback (management's been chipping away at the share count) and you've got two levers working at once. Higher margins. Fewer shares. That's how modest revenue growth turns into faster per-share earnings growth.
State politics matter here, too. The 2026 midterms put new governors and legislatures in charge, and fresh state program rollouts usually follow. Incumbent vendors with existing relationships tend to get the first call. You want to be positioned ahead of that, not chasing it.
A Dividend With Room to Climb
Here's where it gets compelling for income folks. Maximus pays roughly $1.32 annualized. That's a 2.08% trailing yield at today's price.
Be clear on the record: it's lumpy, not steady. Maximus held its quarterly payout at $0.28 from late 2019 into 2023, raised it to $0.30, then lifted it 10% to $0.33 in January 2026. The payout ratio sits around 20% of earnings. Room to keep raising it? Plenty.
Compare that to the household-name dividend plays trading at stretched multiples with payout ratios north of 60%. Maximus gives you yield, growth optionality, and valuation upside in one wrapper. That combo is rare in October 2026.
Action: If you're building an income book, this belongs in the "quiet compounder" bucket. Smaller sizing. Longer hold. Let the dividend growth do its thing. |
Before The Vote (Sponsored)
The man CNBC dubbed “The Prophet” believes the 2026 midterm elections could create a major wealth-creation opportunity for investors who position themselves early enough.
Who is “The Prophet”?
While many investors may wait until the results are in, Whitney Tilson believes the biggest opportunity could come BEFORE Election Day.
Why before the vote?
That’s why he’s showing you how you can position your portfolio ahead of what could be one of the most important market catalysts of the year.
Watch for free here.
*This ad is sent on behalf of Stansberry Research, 1125 N Charles St, Baltimore, MD 21201. If you would like to optout from receiving offers from Stansberry Research please click here.
Where This Thesis Could Break
Risks are real. The big one is customer concentration. The U.S. Federal government is Maximus's largest customer, and when Washington gets dysfunctional (shutdowns, CRs, program cuts), Maximus feels it in delayed starts and dragged-out procurement. One buyer can swing a huge piece of your revenue with a single decision.
Second risk: automation and AI eating the call-center model. If a competitor cracks a lower-cost AI-powered benefits intake system, pricing pressure shows up at renewal. Management is investing to stay ahead. Keep this risk on your radar.
Third: political cycle risk. New administrations reshuffle agency priorities, and some of Maximus's biggest contracts touch areas (Medicaid, student loans, workforce development) that are politically combustible.
These risks are why the stock is cheap. Just know what you're buying.
My Take
If you want yield, valuation upside, and a company whose dividend has room to grow for the next decade, Maximus checks boxes most popular names don't. Boring business. Sticky customers. Deeply discounted. Catalyst (fiscal Q4) hits within weeks.
You won't be bragging about this one at dinner. But if the market finally gives credit for the margin mix and the buybacks, a move toward $85 to $95 adds roughly 35% to 50% on top of a growing dividend. That's the trade I want on, and I'd rather own it before the print than chase it after.
Setup Scorecard
Entry Zone: $60 to $64
Target: $85 to $95 over 9 to 12 months
Stop Loss: Reassess below $54
Catalyst Timeline: Fiscal Q4 2026 earnings on November 19, 2026, fiscal 2027 guidance update, continued contract bookings disclosure
Confidence Level: Medium-High. Valuation gap is wide, dividend is well-covered, catalyst is near. The one thing holding me back from going higher is federal customer concentration.
That’s all for today’s edition of the Dividend Brief.
Thanks for reading, and if you have any feedback or dividend stocks you want me to take a look at, just reply to this email!
—Noah Zelvis
DividendBrief.com
